相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
Rajiv Agarwal et al.
EUROPEAN HEART JOURNAL (2021)
Linking Kidney and Cardiovascular Complications in Diabetes-Impact on Prognostication and Treatment: The 2019 Edwin Bierman Award Lecture
Peter Rossing et al.
DIABETES (2021)
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice
Megumi Oshima et al.
KIDNEY INTERNATIONAL (2021)
Incretin-based drugs and the kidney in type 2 diabetes: choosing between DPP-4 inhibitors and GLP-1 receptor agonists
Johannes F. E. Mann et al.
KIDNEY INTERNATIONAL (2021)
KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease Abstracts
[Anonymous]
KIDNEY INTERNATIONAL (2021)
Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for diabetes after solid organ transplantation
Lale A. Ertuglu et al.
TRANSPLANT INTERNATIONAL (2021)
The Use of HbA1c, Glycated Albumin and Continuous Glucose Monitoring to Assess Glucose Control in the Chronic Kidney Disease Population Including Dialysis
Tobias Bomholt et al.
NEPHRON (2021)
Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
Rajiv Agarwal et al.
EUROPEAN HEART JOURNAL (2021)
2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
John B. Buse et al.
DIABETES CARE (2020)
Diabetes mellitus in chronic kidney disease: Biomarkers beyond HbA1c to estimate glycemic control and diabetes-dependent morbidity and mortality
Sidar Copur et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2020)
Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment
Ian H. de Boer et al.
KIDNEY INTERNATIONAL (2020)
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics
David C. Wheeler et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2020)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Dapagliflozin in Patients with Chronic Kidney Disease
Hiddo J. L. Heerspink et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
George L. Bakris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN) Phase 3 Randomized Controlled Clinical Trial
Sadayoshi Ito et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2020)
Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials
Johannes F. E. Mann et al.
LANCET DIABETES & ENDOCRINOLOGY (2020)
Efficacy and Safety of Empagliflozin in Renal Transplant Recipients With Posttransplant Diabetes Mellitus
Thea Anine Strom Halden et al.
DIABETES CARE (2019)
SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA
Pantelis Sarafidis et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2019)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial
Sadayoshi Ito et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2019)
Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range
Tadej Battelino et al.
DIABETES CARE (2019)
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
Hertzel C. Gerstein et al.
LANCET (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial
George L. Bakris et al.
AMERICAN JOURNAL OF NEPHROLOGY (2019)
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial
Luis M. Ruilope et al.
AMERICAN JOURNAL OF NEPHROLOGY (2019)
Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
Katherine R. Tuttle et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies et al.
DIABETES CARE (2018)
The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
William G. Herrington et al.
CLINICAL KIDNEY JOURNAL (2018)
Diabetes with early kidney involvement may shorten life expectancy by 16 years
Chi Pang Wen et al.
KIDNEY INTERNATIONAL (2017)
Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits
Jens Oellgaard et al.
KIDNEY INTERNATIONAL (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Liraglutide and Renal Outcomes in Type 2 Diabetes
Johannes F. E. Mann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040
K. Ogurtsova et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2017)
Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial
Peter Gde et al.
DIABETOLOGIA (2016)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis
Gemma Currie et al.
BMC NEPHROLOGY (2016)
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy A Randomized Clinical Trial
George L. Bakris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45 mL/min)
Henk Bilo et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient
Christoph Wanner et al.
KIDNEY INTERNATIONAL (2014)
Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy
Linda F. Fried et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes
Hans-Henrik Parving et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Heart failure and nephropathy: Catastrophic and interrelated complications of diabetes
Richard E. Gilbert et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
分享论文
